argenx Announces Positive CHMP Opinion for Subcutaneous

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered...

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Iceland ,Israel ,United States ,United Kingdom ,Japan ,Norway ,Liechtenstein ,America ,Erin Murphy ,Anant Murthy ,European Commission ,Ghent University Hospital ,Committee For Medicinal Products Human Use ,Ghent University ,Immunology Innovation Program ,European Medicines Agency ,European Union Member States ,Medicinal Products ,Human Use ,General Manager ,Union Member States ,North America ,Brussels Stock Exchange Argx ,Argenx Se ,